Chemoresistance and metastasis are the major challenges for the current ovarian cancer
treatment. Understanding the mechanisms of ovarian cancer progression and metastasis is …

Despite optimal surgery and appropriate first-line chemotherapy,∼ 70%–80% of patients
with epithelial ovarian cancer will develop disease relapse. The same modalities as used …

Epithelial ovarian cancer is the most lethal of the gynecologic malignancies, largely due to
the advanced stage at diagnosis in most patients. Screening strategies using ultrasound and …

The natural history of ovarian cancer continues to be characterized by late-stage
presentation, metastatic bulky disease burden and stagnant mortality statistics, despite …

Purpose: The DESKTOP I trial proposed a score for the prediction of complete cytoreduction
in recurrent ovarian cancer. Resectability was assumed if 3 factors were present:(1) …

Background The role of cytoreductive surgery in relapsed ovarian cancer is not clearly
defined. Therefore, patient selection remains arbitrary and depends on the center's …

OBJECTIVE: To determine the relative effect of multiple prognostic variables on overall post-
recurrence survival time among cohorts of patients with recurrent ovarian cancer undergoing …

BACKGROUND The benefit of cytoreductive surgery for patients with recurrent epithelial
ovarian cancer has not been defined clearly. The objective of this study was to identify …

Ovarian cancer accounts for 4% of all cancers in women and is the leading cause of death
from gynaecologic malignancies. Because early-stage ovarian cancer is generally …

Background The standard management of primary ovarian cancer is optimal cytoreductive
surgery followed by platinum‐based chemotherapy. Most women with primary ovarian …